Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. by �씪�꽑�쁺
Promoter Methylation of the Wnt/b-
Catenin Signaling Antagonist Dkk-3
Is Associated With Poor Survival in
Gastric Cancer
Jun Yu, MD, PhD1,2,Qian Tao, PhD2,3, Yuen Y. Cheng, PhD1,2, Kwan Y. Lee, MS2,3,
Simon S. M. Ng, MD4, Kin F. Cheung, MS1,2, Linwei Tian, MD, PhD5, Sun Y. Rha, PhD6,
Ulf Neumann, MD, PhD7, Christoph Ro¨cken, MD, PhD8, Matthias P. A. Ebert, MD, PhD9,
Francis K. L. Chan, MD1,2, and Joseph J. Y. Sung, MD, PhD1,2
BACKGROUND: Abnormal activation of the Wnt/b-catenin signaling pathway is common and critical in the
pathogenesis of digestive cancers. In this study, the authors investigated the promotermethylation of the dick-
kopf homolog 3 geneDkk-3 in these cancers and its prognostic significance in gastric cancer.METHODS: Dkk-
3 methylation was assessed in 173 patients with gastric cancers (including 104 patients who were followed
for up to 4090 days) and in 128 patients with colorectal cancer. Cell growth was evaluated by using a col-
ony-formation assay. For survival analyses, the authors used Kaplan-Meier plots, the log-rank test, and Cox
proportional regression. RESULTS: Dkk-3 was silenced or down-regulated in 12 of 17 gastric cancer cell lines
(70.6%) and in 3 of 9 colon cancer cell lines (33.3%). The loss of gene expression was associated with pro-
moter methylation, which could be restored by demethylating agents. Ectopic expression of Dkk-3 sup-
pressed colony formation. Moreover, methylation of Dkk-3 was detected in 117 of 173 primary gastric
tumors (67.6%) and in 67 of 128 colorectal tumors (52.3%). The clinical significance and the prognostic
value of Dkk-3 methylation also were examined in 104 gastric cancers and in 84 colorectal cancers. Multi-
variate analysis indicated that Dkk-3 methylation was associated significantly and independently with poor
disease survival (relative risk, 2.534; 95% confidence interval, 1.54–4.17; P¼.002) in gastric cancer, but not
in colorectal cancer. Kaplan-Meier survival curves revealed that patients who had Dkk-3 methylated gastric
cancers had a significantly shorter survival (median, 0.76 years) compared with patients who did not have
Dkk-3 methylation (median, 2.68 years; P < .0001; log-rank test). CONCLUSIONS: Epigenetic silencing of
the Dkk-3 gene by promoter methylation was a common event in gastric cancer and was associated with a
poor outcome in such patients. Cancer 2009;115:49–60. VC 2008 American Cancer Society.
KEY WORDS: dickkopf homolog 3, tumor-suppressor gene, digestive tumors, methylation, prognosis.
Received: May 13, 2008; Revised: July 28, 2008; Accepted: August 1, 2008
Published online: December 2, 2008, VC 2008 American Cancer Society
DOI: 10.1002/cncr.23989, www.interscience.wiley.com
Corresponding author: Jun Yu, MD, PhD, Institute of Digestive Disease, Department of Medicine and Therapeutics, Chinese University of Hong Kong,
Room 707A, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Shatin, NT, Hong Kong SAR; Fax: (011) 852-21445330; junyu@cuhk.edu.hk
1Institute of Digestive Disease and Department of Medicine, Chinese University of Hong Kong, Hong Kong SAR; 2Li Ka Shing Institute of Health Sci-
ences, State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Hong Kong SAR; 3Cancer Epigenetics Laboratory, Depart-
ment of Clinical Oncology, Chinese University of Hong Kong, Hong Kong SAR; 4Department of Surgery, Chinese University of Hong Kong, Hong
Kong SAR; 5Stanley Ho Center for Emerging Infectious Disease, Chinese University of Hong Kong, Hong Kong SAR; 6Yonsei Cancer Center, Yonsei
University College of Medicine, Seoul, Korea; 7Department of General, Visceral, and Transplantation Surgery, Charite Campus Virchow-Klinikum, Char-
ite University Hospital, Berlin, Germany; 8Institute of Pathology, Charite University Hospital, Berlin, Germany; 9Department of Medicine II, Technical
University of Munich, Munich, Germany
Cancer January 1, 2009 49
Original Article
Digestive cancers account for about 20% of all can-
cers and are among the leading causes of cancer mortality
in the world. Their incidence varies greatly in different
parts of the world and among various ethnic groups.1,2 It
is recognized increasingly that epigenetic inactivation of
tumor-related genes by promoter methylation plays a cru-
cial role in the development of digestive malignancies.
Methylation in cancer has significant tissue specificity.
For example, the mutL homolog 1 geneMLH1 is methyl-
ated in colorectal cancers3 and gastric cancers4 but is
methylated infrequently in hepatocellular carcinomas
(HCC).5 It is believed that this difference in methylation
is related to a tissue-specific, selective advantage imparted
by the methylation events; however, it also may be related
to tissue-specific exposures.5
Abnormal activation of the Wnt/b-catenin signal-
ing pathway is common and is critical in the pathogene-
sis of digestive cancers. The Wnt pathway consists of
highly conserved, secreted ligands that bind cell-surface
receptors called frizzled and lipoprotein receptor-related
proteins.6,7 The Wnt signaling leads to stabilization and
nuclear translocation of b-catenin, which, in turn, forms
a complex with T-cell factor (TCF) transcription factors
to activate target genes. Many of these target genes are
involved in pathogenesis and tumorigenesis.8,9 Genetic
alterations of adenomatous polyposis coli (APC) and b-
catenin, regulators in the Wnt signaling pathway have
been observed in human colon cancer,10 gastric can-
cer,11,12 and HCC.13 These findings provide evidence
that the activation of the Wnt signaling pathway is
related to the development of digestive cancers. Con-
versely, several antagonists of Wnt signaling have been
identified with 2 functional classes: the secreted frizzled-
related protein (sFRP) class and the dickkopf (Dkk)
class.14 Once Wnt signaling is suppressed by Dkk, b-
catenin is phosphorylated and subsequently targeted for
ubiquitination and degradation. Conversely, the func-
tional loss of Dkk can contribute to the activation of
the Wnt signaling pathway and has a tumor-promoting
effect through the dysregulation of cell proliferation and
differentiation. Therefore, it is hypothesized that that
members of the Dkk class of genes are tumor-suppressor
genes: Dkk-1 reportedly functions as a suppressor of co-
lon cancer cell transformation.15 The Dkk-3 gene,
located on chromosome 11p15.1, is repressed in a vari-
ety of human cancer cell lines and in various types of
human cancers,16–21 which also makes it a candidate tumor-
suppressor gene. Several lines of evidence suggest thatDkk-3
down-regulation in cancers is caused by promoter methyla-
tion.20,22–24 In line with these observations, we also were
able to identify Dkk-3 silencing in colon cancer cell lines
using methylated CpG island amplification combined with
representational difference analysis. However, reports about
the prognostic value of epigenetic silencing of Dkk-3 in can-
cer samples and its clinical implications are rather scarce. We
initiated this study to explore the possible role of Dkk-3 in
gastric and colorectal cancer and its potential relevance to
clinical outcome. We were able to demonstrate that loss of
Dkk-3 expression by promoter methylation is common in
gastric and colorectal cancers. We also demonstrated that
Dkk-3 promotermethylation in primary gastric cancer corre-
lates strongly with a poor patient prognosis and, inmultivari-
ate analyses, is an independent prognostic marker of survival
in patients with gastric cancer.
MATERIALS AND METHODS
Tumor Cell Lines, Primary Tumor Samples,
and Normal Tissue Samples
A series of human tumor cell lines from the digestive sys-
tem were used, including 17 gastric cancer cell lines (Kato
III, YCC1, YCC2, YCC3, YCC6, YCC7, YCC9,
YCC10, YCC11, YCC16, SNU719, MKN28, MKN45,
SNU1, SNU16, NCI87, and AGS) and 8 colon cancer
cell lines (HCT116, DKO, HT-29, Lovo, SW480,
SW48, DLD1, and CaCO2). Human tumors, including
173 gastric cancers (104 with follow-up information) and
128 colorectal cancers (84 with follow-up information),
were obtained from patients at the time of operation. In
addition, 20 age- and sex-matched samples of normal gas-
tric mucosa were included as controls. The samples imme-
diately were snap frozen in liquid nitrogen and stored at
80C. The remaining tissue specimens were fixed in
10% formalin and embedded in paraffin for routine histo-
logic examination. All patients provided informed con-
sent for obtaining the study specimens. The study
protocol was approved by the Ethics Committee of the
Chinese University of Hong Kong. Human normal adult
and fetal tissue RNA samples were purchased
commercially.25
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RNA Extraction and Semiquantitative
Reverse Transcription-Polymerase
Chain Reaction Analysis
Total RNA was extracted from cell pellets using TriRe-
agent (Molecular Research Center, Inc., Cincinnati,
Ohio). Reverse transcription-polymerase chain reaction
(RT-PCR) analysis was performed as described previously
using the Go-Taq polymerase system (Promega,Madison,
Wis) and the GeneAmp RNA PCR system (Applied Bio-
systems, Foster City, Calif) with glyceraldehyde 3-phos-
phate dehydrogenase as a control. The following Dkk-3–
specific primers were used: forward, 50-CACCCTCAAT
GAGATGTTCC-30; and reverse, 50-TGGTCTCATTG
TGATAGCTG-30. The RT-PCR protocol was 32 cycles
with an annealing temperature of 55C.
DNA Extraction and Methylation-Specific
Polymerase Chain Reaction Analysis
Genomic DNA was extracted from the cell pellets and tis-
sues using TriReagent or the QIAamp DNA Mini kit
(Qiagen, Hilden, Germany). DNA was modified chemi-
cally with sodium metabisulphite. The bisulfite-modified
DNA was amplified by using primer pairs that specifically
amplify either methylated or unmethylated sequences of
the Dkk-3 genes. The following methylated Dkk-3–spe-
cific primers were used: sense, 50-TTTCGGGTATC
GGCGTTGTC-30 (positions þ176 to þ195 from the
transcriptional start site); and antisense, 50-ACTAAACC
GAATTACGCTACG-30 (positions þ323 to þ303).
The following unmethylatedDkk-3–specific primers were
used: sense, 50-GTTTTTTTGGGTATTGGTGT
TGTT-30 (positions þ172 to þ195); and antisense,
50-CAACTAAACCAAATTACACTACA-30 (positions
þ325 to þ303). These primer pairs have been tested pre-
viously and do not amplify any bisulphite-untreated
DNA. Methylation-specific PCR (MSP) was performed
for 40 cycles using Taq-Gold polymerase (Applied
Biosystems).
5-Aza-20-Deoxycytidine and Trichostatin
A Treatment
Cells were seeded at a density of 1 106 cells/mL. After
overnight culture, cells were treated with 10 mM of the
DNA demethylating agent 5-aza-20-deoxycytidine (5-
Aza-dC) (Sigma Chemical Company, St. Louis Mo) for
72 hours, with 300 nmol/L of trichostatin A (Sigma) for
additional 24 hours, and then were harvested.
Construction of Dkk-3 Expression Vector
and in Vitro Translation
The Dkk-3 expression vector was generated by PCR clon-
ing with the pcDNA3.1 TOPO TA Expression Kit (Invi-
trogen). Combinational DNA corresponding to full-
length Dkk-3 was obtained by RT-PCR amplification of
normal human thymus RNA (Clontech, Palo Alto, Calif)
with primers unique for Dkk-3. PCR aliquots were subcl-
oned in the pcDNA3.1 TOPO vector. Clones were
screened and sequenced using vector-specific primers.
Colony Formation Assay
Cells from the gastric cancer cell line MKN45 (2 105
cells per well) were transfected with 0.5 lg Dkk-3–
expressing or empty vector (pcDNA3.1) using FuGENE
6 (Roche). Transfected cells were selected with G418 sul-
fate (0.4 mg/mL) (Merck, Darmstadt, Germany) for
2 weeks. Colonies were fixed with methanol/acetone
(1:1), stained with Gentian Violet, and counted. All
experiments were performed in triplicate wells 3 times
each.
Statistical Analysis
The chi-square test was used to compare the frequency of
methylation in tumor and patient characteristics and dis-
tributions of methylation by vital status. Patients’ ages (at
the start of follow-up) by vital status were compared by
using a t test. The relative risk (RR) of death associated
with Dkk-3 methylation and other predictor variables
were estimated first from a univariate Cox proportional
hazards model. Multivariate Cox models also were con-
structed to estimate the RR for Dkk-3 methylation with
adjustments for potential confounding risk factors. Over-
all survival in relation to methylation status was evaluated
by using Kaplan-Meier survival curves and log-rank tests.
All analyses were performed using SAS for Windows, ver-
sion 9 (SAS Institute, Inc., Cary, NC). P < .05 was con-
sidered statistically significant.
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RESULTS
Correlation of Dkk-3 Expression Levels
With Methylation Status in Digestive
Tumor Cell Lines
We compared the expression profiles of HCT116 and
HCT116-DKO cells by using Affymetrix microarray
expression analysis. Dkk-3 is 1 in a group of up-regulated
genes detected in HCT116-DKO cells compared with
HCT116 cells. Because Dkk-3 is expressed widely in nor-
mal adult and fetal tissues (Fig. 1A), we also screened its
expression levels in a series of tumor cell lines from the di-
gestive system by using semiquantitative RT-PCR. Dkk-3
expression was reduced or silenced in 13 of 18 gastric can-
cer cell lines (72.2%) and in 3 of 9 colon cancer cell lines
(33.3%) (Fig. 1B). Next, we examined the role of methyl-
ation in the silencing of Dkk-3. By using MSP, we
detected Dkk-3 methylation in all cell lines that had
silenced or low expression, whereas unmethylated pro-
moter was detected in the cell lines that expressed Dkk-3
(Fig. 1B).
FIGURE 1. (A) Messenger RNA (mRNA) expression of the dickkopf homolog 3 gene Dkk-3 in human normal adult tissue and fetal
tissues by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), with glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) used as the control. (B) Representative Dkk-3 mRNA expression by semiquantitative RT-PCR and promoter
methylation of the Dkk-3 gene by methylation-specific PCR (MSP) in multiple tumor cell lines. Sk. indicates skeletal; LN, lymph
node; U, unmethylated; M, methylated.
FIGURE 2. Expression of the dickkopf homolog 3 gene Dkk-3
could be restored in tumor cells by treatment with 5-Aza-20-
deoxycytidine (A) and trichostatin A (T). Two highly methyl-
ated and silenced cell lines from gastric cancer (SNU719) and
colon cancer (HCT116) were treated. Up-regulated expression
and demethylation (shown by the unmethylated [U] bands)
were detected. MSP indicates methylation-specific polymer-
ase chain reaction; M, methylated.
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FIGURE 3. The dickkopf homolog 3 gene Dkk-3 inhibited tumor cell colony formation. MKN45 cells were transfected with Dkk-3–
expressing cells or with empty vector (pcDNA3.1) and were maintained in the presence of G418 sulfate for 2 weeks. Assays were
performed in triplicate. Quantitative analyses of colony numbers are shown as the mean values  standard deviation. P values
were calculated using the Student t test. The asterisk indicates a statistically significant difference (P¼ .002).
FIGURE 4. Representative methylation-specific polymerase chain reaction analysis results from primary tumors. Dkk3 indicates
dickkopf homolog 3; M, methylated; U, unmethylated; N, normal tissues; T, tumor tissues.
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Dkk-3 Expression Could Be Restored With
5-Aza-Deoxycytidine and Trichostatin
A Treatment in Cancer Cell Lines
To assess whether methylation of Dkk-3 promoter was
associated with transcriptional silencing, we analyzed
Dkk-3 messenger RNA (mRNA) expression in the pres-
ence or absence of the demethylating agent 5-Aza-dC
combined with trichostatin A in 3 heavily methylated and
silenced cell lines from colon cancer (HCT116) and gas-
tric cancer (SNU719). Dkk-3 expression was restored af-
ter demethylation treatment in both cell lines (Fig. 2),
suggesting that CpG methylation contributed directly to
the silencing ofDkk-3 in tumor cells.
Dkk-3 Suppresses Tumor Cell Growth
The frequent silencing of Dkk-3 by methylation in multi-
ple gastric and colon cancer cell lines suggests that Dkk-3
is likely a tumor suppressor. To this end, we expressed an
exogenous Dkk-3 gene in MKN45 cells in which the en-
dogenous gene is silenced by promoter methylation. We
performed colony formation assays using MKN45 cells
that were transfected with a Dkk-3 gene construct
(pcDNA3.1/Dkk-3) or with an empty vector
(pcDNA3.1). The numbers of colonies formed were
counted after 2 weeks in culture with G418 selection. We
observed thatDkk-3 re-expression decreased markedly the
numbers of colonies (Fig. 3).
Dkk-3 Frequently Is Hypermethylated in
Primary Gastric and Colorectal Cancers
Having established that aberrant promoter methylation in
the Dkk-3 gene was correlated with transcriptional silenc-
ing, we investigated Dkk-3methylation in primary gastric
and colorectal cancers. Aberrant methylation was detected
in 67.6% (117 of 173) of gastric cancers and in 52.3% (67
Table 1. Methylation Status of the Dickkopf Homolog 3
Gene Dkk-3 in Tumors and Adjacent Nontumor Tissues
No./Total No. (%)
Origin Tumor Nontumor P
Gastric cancer 117/173 (67.6) 36/104 (34.6) <.0001
Colorectal cancer 67/128 (52.3) 1/20 (5) .005
Table 2. Clinicopathologic Features of Patients With Gastric Cancer According to
Methylation Status of the Dickkopf Homolog 3 Gene Dkk-3 Promoter
Methylated
(n5 64)
Nonmethylated
(n5 40)
Variable No. % No. % P
Age: Mean  SD, y 66.7  12.7 64  13.3 .293
Sex .400
Men 33 57.9 24 42.1
Women 31 66 16 34.04
H. pylori infection .79
Positive 17 51.5 16 48.5
Negative 17 54.8 14 45.2
Lauren type .109
Diffuse 22 71 9 29
Intestinal 22 52.4 20 47.6
Differentiation .242
Poor (or no
differentiation)
23 54.8 19 45.2
Well or moderate 41 66.1 21 33.9
TNM classification .007
I 7 46.7 8 53.3
II 6 33.3 12 66.7
III 22 71 9 29
IV 22 78.6 6 21.4
SD indicates standard deviation.
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of 128) of colorectal cancers. Illustrative examples are
shown in Figure 4. Promoter methylation of Dkk-3 also
was detected in some paired adjacent nontumor tissues,
and methylation was significantly more common in tumor
tissues than in adjacent nontumor tissues (Table 1).
Dkk-3 Is a Predictor of Poor Outcome
in Gastric Cancer
Because a high prevalence ofDkk-3methylation was dem-
onstrated in gastric cancer, the association ofDkk-3meth-
ylation status with clinicopathologic characteristics,
including clinical outcome, was analyzed in 104 gastric
cancer patients with known survival data (median sur-
vival, 503 days; range, 4–4090 days). Methylation of
Dkk-3 was observed more frequently in patients with
advanced tumor stages than in patients with less advanced
tumor stages (P¼ .007). However, there were no correla-
tions between Dkk-3 methylation status and age, sex,
FIGURE 5. Methylation status of the dickkopf homolog 3
gene Dkk-3 predicted clinical outcome in patients with
gastric cancer. Kaplan-Meier analysis of survival was per-
formed according to the presence of Dkk-3 promoter methyl-
ation in 104 patients with gastric cancer. Patients who
had tumors with Dkk-3 methylation had poorer survival com-
pared with patients who had tumors without Dkk-3
methylation.
FIGURE 6. Kaplan-Meier survival curves according to methylation status of the dickkopf homolog 3 gene Dkk-3 in patients with
gastric cancer. Patients with and without Dkk-3 methylation were compared. (A) Patients who had TNM stage I disease exhibited
significantly poorer survival. (B, C) Patients who had TNM stage II and III patients had marginally significant poorer survival. (D)
Patients who had TNM stage IV disease did not differ significantly.
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Helicobacter pylori infection, Lauren type, or tumor differ-
entiation (Table 2).
The Kaplan-Meier estimator of the survivorship
function was used to determine the effects of Dkk-3
methylation on patient survival. The overall survival of
gastric cancer patients with and without Dkk-3 methyla-
tion was compared by using the log-rank test. The over-
all prognosis for patients who had tumors with
methylated Dkk-3 was significantly worse than the prog-
nosis for patients who had tumors without methylation
(P < .0001; log-rank test) (Fig. 5). The data were strati-
fied further according to the TNM tumor classification,
because this is an independent risk factor in patients
with gastric cancer. The Kaplan-Meier survival curves
demonstrated that the survival of patients who had
TNM stage I tumors with Dkk-3 methylation was sig-
nificantly shorter compared with the survival of patients
who had stage I tumors without methylation (Fig. 6). A
similar trend also was noted in patients with stage II
and III tumors (Fig. 6).
Table 3 summarizes the distribution of the clinico-
pathologic characteristics between patients with gastric
cancer who remained alive and those who died. The dis-
ease survival status indicates that advanced TNM tumor
stage and Dkk-3methylation were associated significantly
with vital status (P¼ .002 and P < .0001, respectively),
However, the histologic tumor type according to Lauren
was associated marginally with vital status (P¼ .055),
whereas age, sex, H. pylori infection, and tumor differen-
tiation did not have any prognostic value within the avail-
able follow-up period. In the univariate Cox regression
analysis, Dkk-3 methylation was associated with a highly
significantly increased risk of cancer-related death (RR,
6.40; 95% CI, 3.40-12.1; P < .0001). Lauren type and
tumor stage also were significant predictors of patient out-
come (Table 4). Multivariate analysis indicated that Dkk-
3 methylation was associated with higher mortality (RR,
1.73; 95% CI, 1.03–2.92; P¼ .02) (Table 5). Multivari-
ate analysis revealed that the tumor stage also was associ-
ated with prognosis (Table 5).
Table 3. Distribution of Selected Patient Characteristics by Survival Status
Alive (n5 31) Dead (n5 73)
Variable No. % No. % P
Age: Mean  SD, y 63.4  12.7 66.6  13 .262
Sex .195
Men 20 35.1 37 64.9
Women 11 23.4 36 76.6
H. pylori infection .846
Positive 12 36.4 21 63.6
Negative 12 38.7 19 61.3
Lauren type .055
Intestinal 17 40.5 25 59.5
Diffuse 6 19.3 25 80.7
Differentiation .518
Poor (or no differentiation) 14 33.3 28 66.7
Well or moderate 17 27.4 45 72.6
TNM classification .002
I 7 46.7 8 53.3
II 10 55.6 8 44.4
III 9 29.0 22 71.0
IV 2 7.1 26 92.9
Dkk-3 methylation <.0001
Yes 5 7.8 59 92.2
No 26 65.0 14 35
SD indicates standard deviation; Dkk-3, indicates the dickkopf homolog 3 gene.
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The relation between Dkk-3 methylation and prog-
nosis in 84 patients with colorectal cancer also was ana-
lyzed. Multivariate Cox regression analysis (Table 6) was
conducted to measure the hazard ratio after controlling
for potential confounding factors such as age, sex, TNM
classification, and Dkk-3 methylation. Patients who had
stage I and II disease had a significantly longer survival
compared with patients who had stage IV disease
(P¼ .001). However, there were no significant overall
associations between the methylation status of Dkk-3 and
survival (Table 6). Also in the Kaplan-Meier analysis, the
overall survival of patients who had colorectal cancer with
Dkk-3 methylation did not differ significantly from that
of patients withoutDkk-3methylation (Fig. 7).
DISCUSSION
In the current study, we demonstrated that Dkk-3 tran-
scription frequently is reduced or silenced in gastric and
colon cancer cell lines. This finding supports the recent
observations made by other groups using digestive cancer
cell lines.16,26 Dkk-3 is located on chromosome 11p15,
and Pfeifer observed that this region is an important target
of methylation-mediated genetic imprinting.27 Our study
revealed that silenced or diminished expression of the
Dkk-3 gene is associated closely with promoter methyla-
tion. The inhibition of DNA-methyltransferase activity
by 5-Aza-dC leads to a reversion of methylation and the
re-expression of the silenced gene. Because transcriptional
Table 4. Univariate Cox Regression Analysis of Potential
Prognostic Factors for Patients With Gastric Cancer
Variable RR (95% CI) P
Age 1.01 (0.99–1.03) .307
Sex
Men 0.65 (0.41–1.03) .064
Women 1.00
H. pylori infection
Positive 1.14 (0.61–2.11) .688
Negative 1.00
Lauren type
Diffuse 1.78 (1.02–3.11) .044
Intestinal 1.00
Differentiation
Poor or no differentiation 0.92 (0.57–1.47) .719
Well or moderate 1.00
TNM classification
I 0.24 (0.11–0.55) .0006
II 0.21 (0.09–0.46) .0001
III 0.41 (0.23–0.72) .0022
IV 1.00
Dkk-3 methylation
Yes 6.40 (3.40–12.1) <.0001
No 1.00
RR indicates relative risk; 95% CI, 95% confidence interval; Dkk-3, the
dickkopf homolog 3 gene.
Table 5. Multivariate Cox Regression Analysis of Potential
Prognostic Factors for Patients With Gastric Cancer
Variable RR (95% CI) P
Age 1.00 (0.98–1.03) .971
Sex
Men 0.53 (0.26–1.06) .073
Women 1.00
Lauren type
Diffuse 1.16 (0.61–2.20) .658
Intestinal 1.00
TNM classification
I 0.16 (0.05–0.51) .002
II 0.22 (0.09–0.53) .001
III 0.49 (0.23–1.04) .062
IV 1.00
Dkk-3 methylation
Yes 1.73 (1.03–2.92) .020
No 1.00
RR indicates relative risk; 95% CI, 95% confidence interval; Dkk-3, the
dickkopf homolog 3 gene.
Table 6. Multivariate Cox Regression Analysis of Potential
Prognostic Factors for Patients With Colorectal Cancer
Variable RR (95% CI) P
Age 1.02 (0.99–1.05) .211
Sex
Men 1.37 (0.69–2.74) .367
Women 1.00
TNM classification
I and II 0.21 (0.08–0.54) .001
III 0.62 (0.31–1.27) .193
IV 1.00
Dkk-3 methylation
Yes 1.44 (0.75–2.77) .272
No 1.00
RR indicates relative risk; 95% CI, 95% confidence interval; Dkk-3, the
dickkopf homolog 3 gene.
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silencing mediated by methylation involves the recruit-
ment of histone deacetylase activity,28 the effect of 5-Aza-
dC is augmented by the histone deacetylase inhibitor tri-
chostatin A. Dkk-3 gene mRNA expression was increased
in silenced cell lines after treatment with 5-Aza-dC and
trichostatin A, indicating that methylation is a major
mechanism by which Dkk-3 expression is silenced in di-
gestive cancer cells. In addition, methylation of the Dkk-3
promoter was observed frequently in primary gastric can-
cers (67.6%) and colorectal cancers (52.3%), leading to
the conjecture that epigenetic silencing of the Dkk-3 gene
by promoter methylation is a common event in the tu-
morigenesis of gastric and colorectal cancers.
The functional relevance of the epigenetic silencing
of Dkk-3 determined was further in our cell culture
experiments. We demonstrated that the constitutive
expression of Dkk-3 resulted in a significant decrease in
colony formation. Inhibitory activity on cell growth by
Dkk-3 also has been reported in lung cancer cells,17 osteo-
sarcoma cells,29 and digestive cancer cells.21,26 Collec-
tively, these observations provide strong evidence that the
functional repression of Dkk-3 caused by promoter meth-
ylation is involved in the biology of cancer and thatDkk-3
may function as a suppressor of tumor growth.
At the time of diagnosis, most gastric and colorectal
cancers already have reached an advanced tumor stage and
metastasized to the lymph nodes. Consequently, the prog-
nosis for these patients usually is poor. Therefore, it is still
of paramount importance to identify tumor markers that
predict patient prognosis more accurately than the con-
ventional TNM tumor classification. Because of the high
incidence of Dkk-3 methylation in gastric cancer, we
investigated the clinical significance and prognostic value
of Dkk-3 methylation in 104 patients with gastric cancers
who had known survival data. Most noteworthy, Dkk-3
methylation was correlated significantly with a poor prog-
nosis in our study series and was independent of sex, age,
H. pylori infection, Lauren type, and TNM tumor classifi-
cation, suggesting that Dkk-3 is an independent prognos-
tic marker of prognosis for patients with gastric cancer.
These results raise the possibility that aberrant methyla-
tion ofDkk-3 has an important functional role in progres-
sion of gastric cancer. The potential value of Dkk-3
methylation as a prognostic marker in colorectal cancer
also was investigated in 84 patients who had colorectal
cancers with known survival information. However, Dkk-
3 methylation was not associated with survival in colorec-
tal cancer. This further emphasizes the important histo-
logic differences in the prognostic importance of Dkk-3
methylation in gastrointestinal cancers. Another observa-
tion that Dkk-3 methylation predicts a poor patient out-
come was made in lung adenocarcinomas.30 Moreover,
several previous groups have reported that the methyla-
tion of individual genes had prognostic significance, such
as CDH1 (E-cadherin) in diffuse gastric cancer,31 death-
associated protein (DAP) kinase (DAPK) in lung cancer,32
sFRP-1 in papillary bladder cancer and breast cancer,33,34
and the protein gene product 9.5/ubiquitin carboxyl-ter-
minal esterase L1 gene PGP9.5/UCHL1 in esophageal
cancer.35 Collectively, the results from our study suggest
that Dkk-3 methylation status has potential clinical use as
a prognostic marker in patients with gastric cancer. The
epigenetic silencing of the Dkk-3 gene seems to character-
ize a more aggressiveness genotype of gastric cancer.
Therefore, the specific restoration of Dkk-3 expression
also may be a promising novel treatment target for
patients with gastric cancer and may improve their
prognosis.
In summary, we observed that methylation of the
Dkk-3 promoter and the resultant gene silencing was a
common event in gastric and colorectal cancers. In addi-
tion, we demonstrated that aberrant methylation of Dkk-
3 is an independent predictor of a poor prognosis in
FIGURE 7. Kaplan-Meier survival curve according to methyla-
tion status of the dickkopf homolog 3 gene Dkk-3 in patients
with colorectal cancer. Among 84 colorectal cancer patients,
patients who had tumors with Dkk-3 methylation did not dif-
fer significantly compared with patients who did not have
tumors with Dkk-3 methylation.
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patients with gastric cancer, indicating that these individ-
uals may benefit frommore aggressive treatment.
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